

Eduardo Bonavita

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8299145/eduardo-bonavita-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

2,248
citations

18
h-index

28
g-index

28
ext. papers

2,890
ext. citations

17.4
avg, IF

4.71
L-index

#	Paper	IF	Citations
23	NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. <i>Cell</i> , 2018 , 172, 1022-1037.e14	56.2	674
22	Tumor associated macrophages and neutrophils in cancer. <i>Immunobiology</i> , 2013 , 218, 1402-10	3.4	414
21	PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. <i>Cell</i> , 2015 , 160, 700-714	56.2	233
20	IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. <i>Nature</i> , 2017 , 551, 110-114	40.4	127
19	Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. <i>International Journal of Cancer</i> , 2016 , 139, 446-56	7.5	107
18	Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors. <i>Cell</i> , 2019 , 178, 346-360.e24	56.2	86
17	The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. <i>Immunity</i> , 2014 , 40, 621-32	32.3	81
16	Negative regulatory receptors of the IL-1 family. <i>Seminars in Immunology</i> , 2013 , 25, 408-15	10.7	65
15	Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. <i>Advances in Cancer Research</i> , 2015 , 128, 141-71	5.9	58
14	TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity. <i>Frontiers in Immunology</i> , 2012 , 3, 322	8.4	56
13	The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. <i>Tissue Antigens</i> , 2011 , 77, 271-82		53
12	Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily. <i>Frontiers in Immunology</i> , 2013 , 4, 180	8.4	49
11	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020 , 53, 1215-1229.e8	32.3	49
10	The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic for inflammatory diseases. <i>International Archives of Allergy and Immunology</i> , 2014 , 165, 165-78	3.7	44
9	Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute <i>Pseudomonas aeruginosa</i> lung infection. <i>Infection and Immunity</i> , 2012 , 80, 100-9	3.7	37
8	Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. <i>Journal of Immunology</i> , 2010 , 185, 4641-50	5.3	31
7	The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. <i>Journal of Cellular Physiology</i> , 2010 , 223, 158-67	7	27

6	Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. <i>Cancer Discovery</i> , 2021 , 11, 2602-2619	24.4	21
5	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. <i>Cardiovascular Research</i> , 2019 , 115, 1861-1872	9.9	15
4	Resolving the dark side of therapy-driven cancer cell death. <i>Journal of Experimental Medicine</i> , 2018 , 215, 9-11	16.6	7
3	Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations.. <i>Nature Communications</i> , 2022 , 13, 2063	17.4	3
2	Interplay between Myeloid Cells and Humoral Innate Immunity. <i>Microbiology Spectrum</i> , 2016 , 4,	8.9	2
1	Interplay between Myeloid Cells and Humoral Innate Immunity 2017 , 659-678		